Patent 12083114 was granted and assigned to Disarm Therapeutics on September, 2024 by the United States Patent and Trademark Office.
The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and a neuroprotective agent.